GlassScriptPhysician profile
Elsa S Canales
NPI 1477618429
$4,559.29
in general payments reported to CMS, 2019-2025
29 companies · $1,507 in 2025
The $1,507 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $638 · 2020: $249 · 2021: $415 · 2022: $450 · 2023: $434 · 2024: $867 · 2025: $1,507.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,808.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,807.51 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $847.82 | 2019-2025 | Linzess, Creon, Viberzi |
| Gilead Sciences, INC. | $487.04 | 2019-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $392.61 | 2019-2023 | Trulance |
| Madrigal Pharmaceuticals | $384.10 | 2024-2025 | Rezdiffra, Resmetirom |
| Janssen Biotech, INC. | $367.50 | 2020-2025 | Tremfya, Stelara |
| Daiichi Sankyo INC. | $216.79 | 2019-2023 | Injectafer |
| Ardelyx, INC. | $208.08 | 2024-2025 | Ibsrela |
| Micro-Tech Endoscopy USA, INC. | $175.99 | 2020-2025 | Injection Needles, Forceps, Blueboost |
| Medtronic, INC. | $161.20 | 2024 | Interstim |
| Takeda Pharmaceuticals U.S.A., INC. | $160.50 | 2019-2025 | Entyvio, Eohilia, Gattex |
| Olympus America INC. | $141.21 | 2019-2025 | Single Use Aspiration Needle Na-U200h |
| Pfizer INC. | $129.02 | 2019-2024 | |
| E.R. Squibb & Sons, L.L.C. | $107.82 | 2023 | |
| Novo Nordisk INC | $97.66 | 2021-2025 | Wegovy |
| Nestle Healthcare Nutrition INC. | $91.26 | 2021-2023 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $86.02 | 2021-2024 | Dificid |
| Aimmune Therapeutics, INC. | $63.52 | 2024-2025 | Zenpep |
| Genzyme Corporation | $61.32 | 2024-2025 | |
| Ipsen Biopharmaceuticals, INC | $49.86 | 2025 | Iqirvo |
| Regeneron Healthcare Solutions, INC. | $47.46 | 2024-2025 | Dupixent |
| Evoke Pharma, INC. | $44.39 | 2022 | |
| Celgene Corporation | $44.24 | 2022-2023 | Zeposia |
| Intercept Pharmaceuticals, INC. | $41.54 | 2019-2020 | |
| Redhill Biopharma INC. | $37.77 | 2020-2023 | Talicia |
| Shionogi INC | $35.46 | 2019 | |
| Boston Scientific Corporation | $26.70 | 2020 | |
| Phathom Pharmaceuticals, INC. | $21.51 | 2025 | Voquezna |
| Romark Laboratories, Lc | $16.44 | 2020 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $14.46 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Elsa Canales listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.